Literature DB >> 2992683

Ventromedial thalamic lesions and seizure susceptibility.

S L Moshé, R Okada, B J Albala.   

Abstract

Recent data indicate that the substantia nigra is an important site in a circuitry involved in the modification of various experimental seizures with neocortical and limbic involvement. Since there are no direct nigral projections to either area, we assumed that the nigral effects on seizures are relayed by other sites such as the thalamus. To evaluate this hypothesis we produced bilateral high-radiofrequency thermocoagulative lesions of the ventromedial (VM) thalamic nuclei which receive the nigral efferents in the rat. We determined the susceptibility of lesioned and control adult rats to the development of flurothyl seizures 2 and 4 weeks later. The latency to the onset of a generalized seizure was considered as the convulsive threshold. There were no differences in the mean latencies between the groups. The results suggest that bilateral destruction of the VM thalamic nuclei does not modify the susceptibility to the development of flurothyl seizures in the rat.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2992683     DOI: 10.1016/0006-8993(85)90077-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  3 in total

Review 1.  Organization and physiology of the substantia nigra.

Authors:  H Condé
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

2.  Regional neural activity within the substantia nigra during peri-ictal flurothyl generalized seizure stages.

Authors:  Jana Velísková; Alexandra M Miller; Magda L Nunes; Lucy L Brown
Journal:  Neurobiol Dis       Date:  2005-06-13       Impact factor: 5.996

3.  The striatal dopaminergic catalepsy mechanism is not necessary for the expression of pontine catalepsy produced by carbachol injections into the pontine reticular formation.

Authors:  Z Elazar; N Peleg; M Paz; G Ring
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-08       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.